SMMT
Price:
$14.01
Market Cap:
$10.86B
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). A...[Read more]
Industry
Biotechnology
IPO Date
2015-03-05
Stock Exchange
NASDAQ
Ticker
SMMT
According to Summit Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.81. This represents a change of -42.08% compared to the average of -15.21 of the last 4 quarters.
The mean historical PE Ratio of Summit Therapeutics Inc. over the last ten years is -16.09. The current -8.81 PE Ratio has changed 5.37% with respect to the historical average. Over the past ten years (40 quarters), SMMT's PE Ratio was at its highest in in the July 2018 quarter at 1.32. The PE Ratio was at its lowest in in the October 2017 quarter at -147.60.
Average
-16.09
Median
-10.29
Minimum
-72.09
Maximum
8.04
Discovering the peaks and valleys of Summit Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.05%
Maximum Annual PE Ratio = 8.04
Minimum Annual Increase = -125.77%
Minimum Annual PE Ratio = -72.09
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -12.11 | -83.20% |
| 2024 | -72.09 | 2.05% |
| 2023 | -3.35 | -73.24% |
| 2022 | -12.53 | 230.89% |
| 2021 | -3.79 | -55.22% |
| 2020 | -8.46 | 413.77% |
| 2019 | -1.65 | -120.47% |
| 2019 | 8.04 | -125.77% |
| 2018 | -31.20 | 31.22% |
| 2017 | -23.78 | 26.70% |
The current PE Ratio of Summit Therapeutics Inc. (SMMT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-29.19
5-year avg
-20.77
10-year avg
-16.09
Summit Therapeutics Inc.’s PE Ratio is greater than Roivant Sciences Ltd. (-70.36), greater than BridgeBio Pharma, Inc. (-17.92), greater than Revolution Medicines, Inc. (-22.22), less than Ascendis Pharma A/S (22.87), greater than Ionis Pharmaceuticals, Inc. (-36.99), greater than Exact Sciences Corporation (-95.72), less than Royalty Pharma plc (28.63), less than Moderna, Inc. (-6.17), less than Atrium Therapeutics, Inc. (-3.27), less than Universal Health Services, Inc. (5.88),
| Company | PE Ratio | Market cap |
|---|---|---|
| -70.36 | $21.61B | |
| -17.92 | $13.08B | |
| -22.22 | $32.71B | |
| 22.87 | $13.54B | |
| -36.99 | $12.11B | |
| -95.72 | $20.03B | |
| 28.63 | $23.60B | |
| -6.17 | $19.80B | |
| -3.27 | $211.60M | |
| 5.88 | $9.17B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Summit Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Summit Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Summit Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for Summit Therapeutics Inc. (SMMT)?
What is the highest PE Ratio for Summit Therapeutics Inc. (SMMT)?
What is the 3-year average PE Ratio for Summit Therapeutics Inc. (SMMT)?
What is the 5-year average PE Ratio for Summit Therapeutics Inc. (SMMT)?
How does the current PE Ratio for Summit Therapeutics Inc. (SMMT) compare to its historical average?